Garo Armen, Chairman and CEO at Agenus, shared on LinkedIn:
“The right patient. The right moment.
That is the central challenge – and opportunity – in cancer care.
At ESMO26 Dr. Mehdi Brahmi brought that question to life through a BOT/BAL case in angiosarcoma. The presentation described excellent activity after two months of treatment and attentive tolerability oversight with close monitoring, early recognition, and prompt management.
We are thrilled to see these exciting outcomes for patients with Sarcoma and most proud to work alongside our collaborators in France, where eligible patients with certain advanced soft-tissue sarcomas, colon, and ovarian cancers may access BOT/BAL through the AAC pathway.”
This also can be interesting:
OncoDaily Grand Rounds at ESMO 2026: All You Need to Know About Sarcoma
